Maravai Lifesciences Holdings (MRVI) said Monday that it completed the acquisition of Officinae Bio's DNA and RNA business.
The company said the deal combines Officinae Bio's AI-driven mRNA design platforms with Maravai's and TriLink BioTechnologies' expertise in drug substance manufacturing, offering customers advanced technologies designed to achieve efficient progression from mRNA sequence optimization to clinical testing and commercial manufacturing.
Davide De Lucrezia, chief executive officer of Officinae Bio, will continue to lead the Officinae Bio team, now part of Maravai's Nucleic Acid Production segment, it added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。